Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Medical Genetics
Published in: BMC Medical Genetics 1/2013

Open Access 01-12-2013 | Research article

Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study

Authors: Tyren M Dodgen, Warren E Hochfeld, Heidi Fickl, Sahle M Asfaha, Chrisna Durandt, Paul Rheeder, Britt I Drögemöller, Galen E B Wright, Louise Warnich, Christiaan DJ Labuschagne, Antoinette van Schalkwyk, Andrea Gaedigk, Michael S Pepper

Published in: BMC Medical Genetics | Issue 1/2013

Login to get access

Abstract

Background

Adverse drug reactions and lack of therapeutic efficacy associated with currently prescribed pharmacotherapeutics may be attributed, in part, to inter-individual variability in drug metabolism. Studies on the pharmacogenetics of Cytochrome P450 (CYP) enzymes offer insight into this variability. The objective of this study was to compare the AmpliChip CYP450 Test® (AmpliChip) to alternative genotyping platforms for phenotype prediction of CYP2C19 and CYP2D6 in a representative cohort of the South African population.

Methods

AmpliChip was used to screen for thirty-three CYP2D6 and three CYP2C19 alleles in two different cohorts. As a comparison cohort 2 was then genotyped using a CYP2D6 specific long range PCR with sequencing (CYP2D6 XL-PCR + Sequencing) platform and a PCR-RFLP platform for seven CYP2C19 alleles.

Results

Even though there was a low success rate for the AmpliChip, allele frequencies for both CYP2D6 and CYP2C19 were very similar between the two different cohorts. The CYP2D6 XL-PCR + Sequencing platform detected CYP2D6*5 more reliably and could correctly distinguish between CYP2D6*2 and *41 in the Black African individuals. Alleles not covered by the AmpliChip were identified and four novel CYP2D6 alleles were also detected. CYP2C19 PCR-RFLP identified CYP2C19*9,*15, *17 and *27 in the Black African individuals, with *2, *17 and *27 being relatively frequent in the cohort. Eliminating mismatches and identifying additional alleles will contribute to improving phenotype prediction for both enzymes. Phenotype prediction differed between platforms for both genes.

Conclusion

Comprehensive genotyping of CYP2D6 and CYP2C19 with the platforms used in this study, would be more appropriate than AmpliChip for phenotypic prediction in the South African population. Pharmacogenetically important novel alleles may remain undiscovered when using assays that are designed according to Caucasian specific variation, unless alternate strategies are utilised.
Appendix
Available only for authorised users
Literature
1.
Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001, 286 (18): 2270-2279. 10.1001/jama.286.18.2270.CrossRefPubMed
2.
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007, 116 (3): 496-526. 10.1016/j.pharmthera.2007.09.004.CrossRefPubMed
3.
Kashuba AD, Bertino JSJ: Mechanisms of drug interactions I. Drug Interactions in Infectious Diseases. Edited by: Piscitelli SC, Rodvold KA. 2005, Totowa, NJ: Humana Press, 13-40. 2CrossRef
4.
Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006, 58 (3): 521-590. 10.1124/pr.58.3.6.CrossRefPubMed
5.
Ingelman-Sundberg M: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004, 25 (4): 193-200. 10.1016/j.tips.2004.02.007.CrossRefPubMed
6.
Johansson I, Ingelman-Sundberg M: Genetic polymorphism and toxicology–with emphasis on cytochrome p450. Toxicol Sci. 2011, 120 (1): 1-13. 10.1093/toxsci/kfq374.CrossRefPubMed
7.
de Leon J, Susce MT, Johnson M, Hardin M, Maw L, Shao A, Allen AC, Chiafari FA, Hillman G, Nikoloff DM: DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr. 2009, 14 (1): 19-34.PubMed
8.
de Leon J, Armstrong SC, Cozza KL: Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006, 47 (1): 75-85. 10.1176/appi.psy.47.1.75.CrossRefPubMed
9.
Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, Chabert J, Dayer P, Hochstrasser D, Rossier MF: The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009, 9 (1): 34-41. 10.1038/tpj.2008.7.CrossRefPubMed
10.
Heller T, Kirchheiner J, Armstrong VW, Luthe H, Tzvetkov M, Brockmoller J, Oellerich M: AmpliChip CYP450 GeneChip ®: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit. 2006, 28 (5): 673-677. 10.1097/01.ftd.0000246764.67129.2a.CrossRefPubMed
11.
Nikoloff D, Shim JC, Fairchild M, Patten N, Fijal BA, Koch WH, MacPherson A, Flockhart D, Yoon YR, Yoon JS, Kim YH, Shin JG: Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J. 2002, 2 (6): 400-407. 10.1038/sj.tpj.6500138.CrossRefPubMed
12.
Ishida S, Soyama A, Saito Y, Murayama N, Saeki M, Sai K, Ozawa S, Sawada J: Determination of CYP2D6 gene alleles by the CYP450 probe array using the Affymetrix GeneChip system: comparison with sequencing results. Drug Metab Pharmacokinet. 2002, 17 (2): 157-160. 10.2133/dmpk.17.157.CrossRefPubMed
13.
Altés A, Paré L, del Rio E, Alonso C, Barnadas A, Baiget M, Ramόn y Cajal T: Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat. 2010, 119 (1): 33-38. 10.1007/s10549-009-0328-y.CrossRefPubMed
14.
Gaedigk A, Coetsee C: The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol. 2008, 64 (5): 465-475. 10.1007/s00228-007-0445-7.CrossRefPubMed
15.
Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C: Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics. 2009, 3 (2): 169-190.CrossRefPubMedPubMedCentral
16.
Warnich L, Dandara C, I Drogemoller B S Pepper M EB Wright G: Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation. Curr Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacog. 2011, 9 (3): 191-207. 10.2174/187569211796957575.CrossRef
17.
Wright GE, Niehaus DJ, Drogemoller BI, Koen L, Gaedigk A, Warnich L: Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet. 2010, 74 (4): 340-350. 10.1111/j.1469-1809.2010.00585.x.CrossRefPubMed
18.
Drögemöller BI, Wright GE, Niehaus DJ, Koen L, Malan S, Da Silva DM, Hillermann-Rebello R, La Grange AM, Venter M, Warnich L: Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics. 2010, 11 (8): 1095-1103. 10.2217/pgs.10.90.CrossRefPubMed
19.
Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI: Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol. 2008, 65 (3): 396-406. 10.1111/j.1365-2125.2007.03034.x.CrossRefPubMed
20.
de Wit E, Delport W, Rugamika CE, Meintjes A, Moller M, van Helden PD, Seoighe C, Hoal EG: Genome-wide analysis of the structure of the South African Coloured Population in the Western Cape. Hum Genet. 2010, 128 (2): 145-153. 10.1007/s00439-010-0836-1.CrossRefPubMed
21.
Patterson N, Petersen DC, van der Ross RE, Sudoyo H, Glashoff RH, Marzuki S, Reich D, Hayes VM: Genetic structure of a unique admixed population: implications for medical research. Hum Mol Genet. 2010, 19 (3): 411-419. 10.1093/hmg/ddp505.CrossRefPubMed
22.
Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E: Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem. 2000, 46 (8 Pt 1): 1072-1077.PubMed
23.
Gaedigk A, Ndjountche L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, Brousseau DC, McCarver DG, Johnson JA, Alander SW, Wayne Riggs K, Steven Leeder J: Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther. 2007, 81 (2): 242-251. 10.1038/sj.clpt.6100033.CrossRefPubMed
24.
Werle E, Schneider C, Renner M, Volker M, Fiehn W: Convenient single-step, one tube purification of PCR products for direct sequencing. Nucleic Acids Res. 1994, 22 (20): 4354-4355. 10.1093/nar/22.20.4354.CrossRefPubMedPubMedCentral
25.
Gaedigk A, Bradford LD, Alander SW, Leeder JS: CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos. 2006, 34 (4): 563-569. 10.1124/dmd.105.008292.CrossRefPubMed
26.
27.
28.
Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouze P, Brunak S: Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information. Nucleic Acids Res. 1996, 24 (17): 3439-3452. 10.1093/nar/24.17.3439.CrossRefPubMedPubMedCentral
29.
Brunak S, Engelbrecht J, Knudsen S: Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol. 1991, 220 (1): 49-65. 10.1016/0022-2836(91)90380-O.CrossRefPubMed
30.
Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS: The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008, 83 (2): 234-242. 10.1038/sj.clpt.6100406.CrossRefPubMed
31.
Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21 (2): 263-265. 10.1093/bioinformatics/bth457.CrossRefPubMed
32.
Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, Ramsay M: Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics. 2011, 12 (12): 1663-1670. 10.2217/pgs.11.106.CrossRefPubMed
33.
Ikediobi O, Aouizerat B, Xiao Y, Gandhi M, Gebhardt S, Warnich L: Analysis of pharmacogenetic traits in two distinct South African populations. Hum Genomics. 2011, 5 (4): 265-282.CrossRefPubMedPubMedCentral
34.
Dandara C, Masimirembwa CM, Magimba A, Sayi J, Kaaya S, Sommers DK, Snyman JR, Hasler JA: Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol. 2001, 57 (1): 11-17. 10.1007/s002280100282.CrossRefPubMed
35.
Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A: Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics. 2009, 19 (2): 170-179. 10.1097/FPC.0b013e32831ebb30.CrossRefPubMed
36.
Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006, 79 (1): 103-113. 10.1016/j.clpt.2005.10.002.CrossRefPubMed
37.
Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Drozdzik M: Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol. 2006, 62 (10): 877-880. 10.1007/s00228-006-0183-2.CrossRefPubMed
38.
Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E: Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2008, 83 (2): 322-327. 10.1038/sj.clpt.6100291.CrossRefPubMed
39.
Kearns GL, Leeder JS, Gaedigk A: Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos. 2010, 38 (6): 894-897. 10.1124/dmd.109.030601.CrossRefPubMedPubMedCentral
40.
Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG: Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics. 2009, 10 (1): 43-49. 10.2217/14622416.10.1.43.CrossRefPubMed
41.
Gaedigk A, Ndjountche L, Leeder JS, Bradford LD: Limited association of the 2988 g > a single nucleotide polymorphism with CYP2D641 in black subjects. Clin Pharmacol Ther. 2005, 77 (3): 228-30. 10.1016/j.clpt.2004.10.014. author reply 230–1CrossRefPubMed
42.
Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006, 108 (7): 2244-2247. 10.1182/blood-2006-04-013052.CrossRefPubMed
43.
Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009, 302 (8): 849-857. 10.1001/jama.2009.1232.CrossRefPubMedPubMedCentral
44.
Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS: Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010, 304 (16): 1821-1830. 10.1001/jama.2010.1543.CrossRefPubMedPubMedCentral
45.
Gaedigk A, Eklund JD, Pearce RE, Leeder JS, Alander SW, Phillips MS, Bradford LD, Kennedy MJ: Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype. Clin Pharmacol Ther. 2007, 81 (6): 817-820. 10.1038/sj.clpt.6100125.CrossRefPubMed
Metadata
Title
Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study
Authors
Tyren M Dodgen
Warren E Hochfeld
Heidi Fickl
Sahle M Asfaha
Chrisna Durandt
Paul Rheeder
Britt I Drögemöller
Galen E B Wright
Louise Warnich
Christiaan DJ Labuschagne
Antoinette van Schalkwyk
Andrea Gaedigk
Michael S Pepper
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2013
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/1471-2350-14-20

Other articles of this Issue 1/2013

BMC Medical Genetics 1/2013 Go to the issue

Research article

Association between paraoxonase gene and stroke in the Han Chinese population

Case report

Disruption of AP3B1by a chromosome 5 inversion: a new disease mechanism in Hermansky-Pudlak syndrome type 2

Research article

Three novel germ-line VHL mutations in Hungarian von Hippel-Lindau patients, including a nonsense mutation in a fifteen-year-old boy with renal cell carcinoma

Research article

SOD2gene Val16Ala polymorphism is associated with macroalbuminuria in Mexican Type 2 Diabetes patients: a comparative study and meta-analysis

Case report

Compound heterozygosity of predicted loss-of-function DESvariants in a family with recessive desminopathy

Research article

The silence of MUC2 mRNA induced by promoter hypermethylation associated with HBV in Hepatocellular Carcinoma